Following discovery of the cystic fibrosis transmembrane conductance regulator (CFTR)
gene in 1989 and subsequent elucidation of the varied CFTR protein abnormalities that …

Cystic fibrosis is a multiorgan disease caused by impaired function of the cystic fibrosis
transmembrane conductance regulator (CFTR). Since the introduction of the CFTR …

Triple combination therapy with the CFTR modulators elexacaftor (ELX), tezacaftor (TEZ)
and ivacaftor (IVA) has been qualified as a game changer in cystic fibrosis (CF). We provide …

Highly effective modulator therapies (HEMTs) have revolutionised the management
approach of most patients living with cystic fibrosis (CF) who have access to these therapies …

Background Prognosis and disease severity in cystic fibrosis (CF) are linked to declining
lung function. To characterise lung function by the number of adults in countries with …

Cystic fibrosis (CF) is a potentially fatal monogenic disease that causes a progressive
multisystemic pathology. Over the last decade, the introduction of CF transmembrane …

Background: Elexacaftor-Tezacaftor-Ivacaftor (ELE/TEZ/IVA) is believed to be an effective
and well-tolerated treatment for cystic fibrosis (CF), but the exact efficacy and safety profile …

Cystic fibrosis (CF) is a genetic disease caused by variants in the gene encoding for the CF
transmembrane conductance regulator (CFTR) protein, a chloride and bicarbonate channel …

This past year, there were many important advances for patients with cystic fibrosis (CF). Of
the many publications related to CF in 2023, there was further evaluation of highly effective …

Remarkable medical advancements have been made for people with cystic fibrosis (CF) in
recent years, with an abundance of research continuing to be conducted worldwide. With …